NICOTINAMIDE RIBOSIDE FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED NEUROPATHY, DRY EYE SYNDROME, AND HEARING LOSS
Iowa City, IA
Congressional District Code:
September 2020 -
FY 2021 Funding Amount:
Total Award Amount (all years):
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt:
Continuing advances in detection and treatment have greatly increased the number of cancer survivors, as well as more Veterans living with cancer because of continued therapy. However, while these therapies prolong life, they are accompanied by adverse effects that introduce functional limitations and significantly reduce quality of life of Veterans. For example, taxane and platinum-based chemotherapies produce very painful and debilitating peripheral neuropathies that greatly diminish patients’...